NeuroVive Pharmaceutical ABのEPS 1株当たり利益 は-0.01です。
1株当たり利益（EPS) は、当社の1株当たり利益です。それは株式の希釈を考慮に入れ、 過去12ヶ月間にカウントされます。
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.